CN118829642A - 二酰基甘油激酶(DGK)α抑制剂及其用途 - Google Patents
二酰基甘油激酶(DGK)α抑制剂及其用途 Download PDFInfo
- Publication number
- CN118829642A CN118829642A CN202380024556.1A CN202380024556A CN118829642A CN 118829642 A CN118829642 A CN 118829642A CN 202380024556 A CN202380024556 A CN 202380024556A CN 118829642 A CN118829642 A CN 118829642A
- Authority
- CN
- China
- Prior art keywords
- heterocycloalkyl
- cycloalkyl
- alkyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022078655 | 2022-03-01 | ||
| CNPCT/CN2022/078655 | 2022-03-01 | ||
| CNPCT/CN2022/091215 | 2022-05-06 | ||
| CN2022091215 | 2022-05-06 | ||
| CNPCT/CN2022/128282 | 2022-10-28 | ||
| CN2022128282 | 2022-10-28 | ||
| CN2023071962 | 2023-01-12 | ||
| CNPCT/CN2023/071962 | 2023-01-12 | ||
| PCT/CN2023/078973 WO2023165509A1 (en) | 2022-03-01 | 2023-03-01 | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118829642A true CN118829642A (zh) | 2024-10-22 |
Family
ID=87883015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380024556.1A Pending CN118829642A (zh) | 2022-03-01 | 2023-03-01 | 二酰基甘油激酶(DGK)α抑制剂及其用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250214990A1 (https=) |
| EP (1) | EP4486745A4 (https=) |
| JP (1) | JP2025507915A (https=) |
| CN (1) | CN118829642A (https=) |
| AR (1) | AR128668A1 (https=) |
| TW (1) | TW202342478A (https=) |
| WO (1) | WO2023165509A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4486741A4 (en) | 2022-03-01 | 2026-04-08 | Insilico Medicine Ip Ltd | Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses |
| EP4661869A1 (en) | 2023-02-06 | 2025-12-17 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators |
| WO2025051110A1 (en) * | 2023-09-04 | 2025-03-13 | Insilico Medicine Ip Limited | Combinations treatments of diacylglycerol kinase (dgk) alpha inhibitors and other therapies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011075747A1 (en) * | 2009-12-18 | 2011-06-23 | Glaxosmithkline Llc | Therapeutic compounds |
| KR102767739B1 (ko) * | 2018-06-27 | 2025-02-12 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
| US20230062100A1 (en) * | 2019-11-28 | 2023-03-02 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| BR112022012179A2 (pt) * | 2019-12-23 | 2022-09-06 | Bristol Myers Squibb Co | Compostos de quinazolina substituída úteis como ativadores de célula t |
| IL294032A (en) * | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| MX2023014762A (es) * | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
-
2023
- 2023-03-01 JP JP2024552219A patent/JP2025507915A/ja active Pending
- 2023-03-01 EP EP23762907.6A patent/EP4486745A4/en active Pending
- 2023-03-01 CN CN202380024556.1A patent/CN118829642A/zh active Pending
- 2023-03-01 WO PCT/CN2023/078973 patent/WO2023165509A1/en not_active Ceased
- 2023-03-01 AR ARP230100508A patent/AR128668A1/es unknown
- 2023-03-01 US US18/841,639 patent/US20250214990A1/en active Pending
- 2023-03-01 TW TW112107273A patent/TW202342478A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4486745A1 (en) | 2025-01-08 |
| WO2023165509A1 (en) | 2023-09-07 |
| EP4486745A4 (en) | 2026-03-11 |
| TW202342478A (zh) | 2023-11-01 |
| AR128668A1 (es) | 2024-06-05 |
| US20250214990A1 (en) | 2025-07-03 |
| JP2025507915A (ja) | 2025-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118829642A (zh) | 二酰基甘油激酶(DGK)α抑制剂及其用途 | |
| CN118871438A (zh) | 二酰基甘油激酶(DGK)α抑制剂及其用途 | |
| CN114075195B (zh) | 嘧啶酮衍生物及其在药物中的应用 | |
| WO2012149567A1 (en) | Kinase inhibitors | |
| KR102755652B1 (ko) | 고리형 디뉴클레오티드 유사체, 이의 약학 조성물 및 용도 | |
| CN118974048A (zh) | 膜相关的酪氨酸和苏氨酸特异性cdc2抑制激酶(pkmyt1)抑制剂及其用途 | |
| CN119630670A (zh) | TNFα活性调节剂及其用途 | |
| CN119630662A (zh) | Cbl-b抑制剂及其应用方法 | |
| WO2023165525A1 (en) | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof | |
| CN118871439A (zh) | 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制剂及其用途 | |
| CN113773335A (zh) | 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途 | |
| WO2020163118A1 (en) | Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof | |
| CN121941684A (zh) | Cbl-b抑制剂及其使用方法 | |
| CN121175313A (zh) | Nlrp3炎症小体抑制剂及其用途 | |
| AU2023224815A1 (en) | Compound as fak inhibitor and use thereof | |
| TW202237101A (zh) | Ｃｔｌａ－４小分子降解劑及其應用 | |
| WO2024061300A1 (en) | Inhibitors of trex1 and uses thereof | |
| EA052540B1 (ru) | Ингибиторы альфа-диацилглицеринкиназы (дгк) и способы их применения | |
| HK40117800A (zh) | 二酰基甘油激酶(DGK)α抑制剂及其用途 | |
| WO2025261355A1 (en) | Werner syndrome recq helicase (wrn) inhibitors and methods of uses thereof | |
| WO2023193759A1 (en) | Hpk1 antagonists and uses thereof | |
| CN120712269A (zh) | Fgfr2和fgfr3的抑制剂及其用途 | |
| HK40116343A (zh) | 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制剂及其用途 | |
| WO2025252075A1 (en) | Novel compounds as salt-inducible kinases inhibitors and uses thereof | |
| CN121554466A (zh) | 一种fgfr3抑制剂及其组合物和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |